Thomas Gajewski, David Steinberg. (CRI, Pyxis)

Bay­er, Long­wood back star re­searcher's deep dive in­to the tu­mor mi­croen­vi­ron­ment for new I/O tar­gets

From PD-1 tar­get­ing to the RAS path­way to the STING com­plex, Thomas Gajew­s­ki has spent the past two decades of his ca­reer de­cod­ing the var­i­ous ways the im­mune sys­tem can be un­leashed to de­fend against can­cer. So when the Uni­ver­si­ty of Chica­go pro­fes­sor comes around to putting all his find­ings in­to a new plat­form for find­ing new tar­gets, VCs and phar­ma groups alike pay at­ten­tion.

“He’s been study­ing T cells for 20 years, plus he’s one of the world’s lead­ers if not the world leader in the space,” David Stein­berg, part­ner at Long­wood Fund, said. “Fur­ther­more, let me add he did a lot of the foun­da­tion­al re­search and al­so some of the sem­i­nal clin­i­cal tri­als in the ex­ist­ing set of I/O agents. He un­der­stands the space re­al­ly well, he un­der­stands the cur­rent strengths, and I think he un­der­stood re­al­ly well what was miss­ing, so he knew where to look.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.